Hengrui medicine independently develops new anti-tumor drugs and is approved to carry out clinical trials

On July 31, Hengrui pharmaceutical announced that its company and its subsidiaries Shanghai Hengrui Pharmaceutical Co., Ltd and Suzhou shengdia biomedical Co., Ltd have recently received the notice of clinical trial approved and issued by the State Drug Administration, and will carry out the clinical trial in the near future Shr-1316 combined with shr-1501 was used in patients with advanced cancer who failed in standard treatment As a PD-L1 monoclonal antibody, SHR-1316 can release the immunosuppressive effect mediated by PD-L1, enhance the function of killing T cells, and play the role of mobilizing the immune system to remove tumor cells in the body Shr-1501, as a fusion protein of interleukin-15 (IL-15), stimulates the proliferation of T cells, B cells and NK cells in vivo, and plays the role of mobilizing the immune system to remove foreign matters (such as tumors) in vivo Compared with IL-2, shr-1501 has no mechanism of stimulating Treg proliferation and activating to induce T cell apoptosis Shr-1316 and shr-1501 are independently developed products of the company According to the inquiry, at present, there are similar products of atrezolizumab (trade name tecentriq ®), avelumab (trade name bavencio ®) and durvalumab (trade name imfinzi ®) approved for sale in the United States, but no similar products approved for sale in China In China, cs1001 and other similar products are in clinical trial stage At present, there are several products with the same target, such as alt-803, in the clinical trial stage in foreign countries, but no products with the same target are in the clinical trial stage in China At home and abroad, no products with the same target have been approved for listing, and there is no relevant sales data According to the IMS database, the total global sales of atezolizumab, durvalumab and avelumab in 2018 were about $1456 million Up to now, the R & D cost of shr-1316 project is about 97.59 million yuan, and that of shr-1501 project is about 33.03 million yuan.